[{"address1": "10578 Science Center Drive", "address2": "Suite 125", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 401 7900", "website": "https://www.aviditybiosciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 253, "companyOfficers": [{"maxAge": 1, "name": "Dr. Troy Edward Wilson J.D., Ph.D.", "age": 54, "title": "Co-Founder & Chairman", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": 67500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sarah  Boyce", "age": 51, "title": "President, CEO & Director", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": 1046836, "exercisedValue": 1081861, "unexercisedValue": 19581712}, {"maxAge": 1, "name": "Mr. Michael F. MacLean", "age": 57, "title": "Chief Financial & Chief Business Officer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 701636, "exercisedValue": 0, "unexercisedValue": 2695684}, {"maxAge": 1, "name": "Dr. W. Michael Flanagan Ph.D.", "age": 61, "title": "Chief Scientific & Technical Officer", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 678736, "exercisedValue": 0, "unexercisedValue": 249310}, {"maxAge": 1, "name": "Ms. Teresa  McCarthy", "age": 59, "title": "Chief Human Resources Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 665136, "exercisedValue": 0, "unexercisedValue": 287661}, {"maxAge": 1, "name": "Mr. Eric B. Mosbrooker", "age": 55, "title": "Chief Strategy Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 42500, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Mark E. Davis", "title": "Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Frank P. McCormick Ph.D.", "age": 73, "title": "Scientific Founder & Member of Scientific Advisory Board", "yearBorn": 1950, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Geoffrey M. Grande C.F.A.", "title": "VP of Investor Relation & Corporate Communication", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John W. Wallen III", "age": 65, "title": "VP of Intellectual Property, General Counsel & Secretary", "yearBorn": 1958, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 9, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 25.35, "open": 25.28, "dayLow": 24.663, "dayHigh": 25.5, "regularMarketPreviousClose": 25.35, "regularMarketOpen": 25.28, "regularMarketDayLow": 24.663, "regularMarketDayHigh": 25.5, "beta": 0.712, "forwardPE": -7.055241, "volume": 295348, "regularMarketVolume": 295348, "averageVolume": 1190981, "averageVolume10days": 1079110, "averageDailyVolume10Day": 1079110, "bid": 24.72, "ask": 25.06, "bidSize": 100, "askSize": 100, "marketCap": 1985414272, "fiftyTwoWeekLow": 4.825, "fiftyTwoWeekHigh": 27.66, "priceToSalesTrailing12Months": 207.67932, "fiftyDayAverage": 19.4182, "twoHundredDayAverage": 10.971975, "currency": "USD", "enterpriseValue": 1381180416, "floatShares": 65632245, "sharesOutstanding": 79719504, "sharesShort": 8616024, "sharesShortPriorMonth": 7731318, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.108100004, "heldPercentInsiders": 0.06413, "heldPercentInstitutions": 0.85405, "shortRatio": 5.79, "shortPercentOfFloat": 0.1093, "impliedSharesOutstanding": 79719504, "bookValue": 6.317, "priceToBook": 3.942536, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -212220000, "trailingEps": -2.91, "forwardEps": -3.53, "enterpriseToRevenue": 144.475, "enterpriseToEbitda": -5.915, "52WeekChange": 0.69225633, "SandP52WeekChange": 0.2565279, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "RNA", "underlyingSymbol": "RNA", "shortName": "Avidity Biosciences, Inc.", "longName": "Avidity Biosciences, Inc.", "firstTradeDateEpochUtc": 1591968600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "78c44541-35ca-3c53-b3fc-50daf7213847", "messageBoardId": "finmb_257084190", "gmtOffSetMilliseconds": -14400000, "currentPrice": 24.905, "targetHighPrice": 71.0, "targetLowPrice": 33.0, "targetMeanPrice": 46.71, "targetMedianPrice": 40.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 595350976, "totalCashPerShare": 7.468, "ebitda": -233496992, "totalDebt": 9852000, "quickRatio": 7.486, "currentRatio": 7.577, "totalRevenue": 9560000, "debtToEquity": 1.967, "revenuePerShare": 0.131, "returnOnAssets": -0.23236999, "returnOnEquity": -0.39341998, "freeCashflow": -86656752, "operatingCashflow": -119064000, "revenueGrowth": -0.208, "operatingMargins": -30.43456, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-12"}]